Stocks › GILD

GILEAD SCIENCES, INC.

GILD·Nasdaq·United States United States·USD
$166.43
-0.10 (-0.06%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
GILD
GILEAD SCIENCES, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GILDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of GILD by members of U.S. Congress · 284 on record · 16 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
Sep 5, 2026 Aug 10, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Aug 8, 2026 Jul 20, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
Aug 8, 2026 Jul 7, 2026 Filing ↗
Tommy TubervilleTommy TubervilleSenate · R · AL GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
Aug 5, 2026 May 8, 2024 Filing ↗
Tommy TubervilleTommy TubervilleSenate · R · AL GILDGILEAD SCIENCES, INC. · Stock Option Purchase
$1,001 - $15,000
Aug 5, 2026 May 10, 2024 Filing ↗
Tommy TubervilleTommy TubervilleSenate · R · AL GILDGILEAD SCIENCES, INC. · Stock Option Purchase
$1,001 - $15,000
Aug 5, 2026 May 10, 2024 Filing ↗
Tommy TubervilleTommy TubervilleSenate · R · AL GILDGILEAD SCIENCES, INC. · Stock Option Purchase
$1,001 - $15,000
Aug 5, 2026 May 10, 2024 Filing ↗
Alan ArmstrongAlan ArmstrongSenate · R · OK GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Jul 21, 2026 Mar 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Stock Sale
$15,001 - $50,000
Jul 7, 2026 Jun 16, 2026 Filing ↗
Jared MoskowitzJared MoskowitzHouse · D · FL GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Jun 19, 2026 May 6, 2026 Filing ↗
Jared MoskowitzJared MoskowitzHouse · D · FL GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Jun 19, 2026 May 6, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Stock Purchase
$15,001 - $50,000
Jun 10, 2026 May 15, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Common Stock Sale
$15,001 - $50,000
May 11, 2026 Apr 13, 2026 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Feb 26, 2026 Jan 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Common Stock Purchase
$15,001 - $50,000
Feb 6, 2026 Jan 29, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA GILDGILEAD SCIENCES, INC. · Common Stock Sale
$1,001 - $15,000
Feb 6, 2026 Jan 23, 2026 Filing ↗
Val T. HoyleVal T. HoyleHouse · D · OR GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
Oct 10, 2025 Sep 23, 2025 Filing ↗
Val T. HoyleVal T. HoyleHouse · D · OR GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Sep 12, 2025 Oct 29, 2024 Filing ↗
Jefferson ShreveJefferson ShreveHouse · R · IN GILDGILEAD SCIENCES, INC. · Stock Sale
$15,001 - $50,000
Jun 22, 2025 May 12, 2025 Filing ↗
Marjorie Taylor GreeneMarjorie Taylor GreeneHouse · R · GA GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
Jun 18, 2025 Jun 6, 2025 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
Jun 11, 2025 May 14, 2025 Filing ↗
John BoozmanJohn BoozmanSenate · R · AR GILDGILEAD SCIENCES, INC. · Stock Sale
$1,001 - $15,000
May 14, 2025 Apr 16, 2025 Filing ↗
Marjorie Taylor GreeneMarjorie Taylor GreeneHouse · R · GA GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
May 6, 2025 May 5, 2025 Filing ↗
Marjorie Taylor GreeneMarjorie Taylor GreeneHouse · R · GA GILDGILEAD SCIENCES, INC. · Stock Purchase
$1,001 - $15,000
May 6, 2025 May 5, 2025 Filing ↗
Jefferson ShreveJefferson ShreveHouse · R · IN GILDGILEAD SCIENCES, INC. · Stock Purchase
$15,001 - $50,000
Apr 11, 2025 Mar 31, 2025 Filing ↗

Whale Activity

Position changes in GILD reported for 2026-09-30 by 2488 institutional filers
Increased: 938New: 224Held: 291Decreased: 807Closed: 128No prior filing: 100
  • Increased938
  • New224
  • Held291
  • Decreased807
  • Closed128
  • No prior filing100
FilerSharesValueChange
BlackRock, Inc.125.2M$18.67Bincreased
VANGUARD CAPITAL MANAGEMENT LLC81.2M$12.10Bincreased
STATE STREET CORP61.0M$9.09Bdecreased
FMR LLC58.3M$8.68Bdecreased
Invesco Ltd.38.7M$5.76Bdecreased
Capital World Investors35.9M$5.36Bdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC35.7M$5.32Bincreased
GEODE CAPITAL MANAGEMENT, LLC30.2M$4.49Bincreased
PRICE T ROWE ASSOCIATES INC /MD/27.7M$4.12Bdecreased
Capital Research Global Investors24.0M$3.57Bincreased
MORGAN STANLEY23.8M$3.54Bdecreased
JPMORGAN CHASE & CO23.1M$3.49Bincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by GILD insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -305.3K2025 Q12025 Q2: -46.0K2025 Q22025 Q3: -75.8K2025 Q32025 Q4: -136.3K2025 Q42026 Q1: -309.3K2026 Q12026 Q2: -68.0K2026 Q22026 Q3: -111.0K2026 Q32026 Q4: -209.1K2026 Q4

Recent Insider Transactions

4,914 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Mercier JohannaChief Comm & Corp Aff Officer Sale −900 $171.69 $155K Nov 16, 2026 Form 4 ↗
Mercier JohannaChief Comm & Corp Aff Officer Sale −13.9K $169.97 $2.4M Nov 16, 2026 Form 4 ↗
Mercier JohannaChief Comm & Corp Aff Officer Sale −13.2K $171.09 $2.3M Nov 16, 2026 Form 4 ↗
Dickinson Andrew DChief Financial Officer Sale −3,000 $171.47 $514K Nov 16, 2026 Form 4 ↗
Kramer Kelly A.Director · Director Sale −4,700 $170.49 $801K Nov 12, 2026 Form 4 ↗
Kramer Kelly A.Director · Director Sale −3,800 $169.44 $644K Nov 12, 2026 Form 4 ↗
Kramer Kelly A.Director · Director Sale −200 $171.44 $34K Nov 12, 2026 Form 4 ↗
Kramer Kelly A.Director · Director Sale −1,676 $168.23 $282K Nov 12, 2026 Form 4 ↗
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp Sale −3,399 $164.11 $558K Nov 6, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −9,810 $175.17 $1.7M Nov 5, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −102.6K $175.16 $18.0M Nov 4, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −7,796 $170.35 $1.3M Nov 2, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −2,000 $171.06 $342K Nov 2, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −1,904 $169.27 $322K Nov 2, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −1,700 $168.10 $286K Nov 2, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −1,600 $167.40 $268K Nov 2, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −15.9K $175.25 $2.8M Oct 30, 2026 Form 4 ↗
Mercier JohannaChief Comm & Corp Aff Officer Sale −3,000 $156.22 $469K Oct 15, 2026 Form 4 ↗
Dickinson Andrew DChief Financial Officer Sale −3,000 $156.22 $469K Oct 15, 2026 Form 4 ↗
O'Day Daniel PatrickChairman & CEO · Director Sale −3,000 $148.63 $446K Oct 1, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding GILD · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
39.4M$4.98B0.22%Jun 30, 2026
VANGUARD 500 INDEX FUND
VANGUARD INDEX FUNDS
32.2M$4.06B0.24%Jun 30, 2026
Invesco QQQ Trust, Series 126.4M$3.33B0.68%Jun 30, 2026
Fidelity 500 Index Fund
Fidelity Concord Street Trust
16.1M$2.36B0.27%Aug 31, 2026
Dodge & Cox Stock Fund
Dodge & Cox Funds
17.3M$2.18B1.84%Jun 30, 2026
iShares Core S&P 500 ETF
iShares Trust
17.1M$2.16B0.24%Jun 30, 2026
Income Fund of America15.5M$2.02B1.36%Jul 31, 2026
State Street(R) SPDR(R) S&P 500(R) ETF Trust15.0M$1.90B0.24%Jun 30, 2026
VANGUARD VALUE INDEX FUND
VANGUARD INDEX FUNDS
11.8M$1.49B0.59%Jun 30, 2026
Fidelity Contrafund11.4M$1.44B0.80%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list GILD's shares (CUSIP 375558103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings

No 13D/13G beneficial-ownership filings on record.

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming gilead sciences as client
$0$5.0M$10.0M$15.0M$20.0M2023 Q1: $3.5M2023 Q2: $2.2M2023 Q3: $3.2M2023 Q4: $2.5M20232024 Q1: $3.5M2024 Q2: $2.4M2024 Q3: $2.9M2024 Q4: $3.4M20242025 Q1: $2.5M2025 Q2: $2.6M2025 Q3: $3.7M2025 Q4: $2.7M20252026 Q1: $4.1M2026 Q2: $2.5M2026 Q3: $9.8M2026
  • GILEAD SCIENCES, INC.GILEAD SCIENCES INC · 2026 Q3 · TRD, BUD, HCR, MMM$2.3M
    Filing ↗
  • GILEAD SCIENCES, INC.GILEAD SCIENCES INC · 2026 Q3 · TRD, HCR, MMM, CPT$6.6M
    Filing ↗
  • TARPLIN, DOWNS & YOUNG, LLCGILEAD SCIENCES, INC. · 2026 Q3 · BUD, HCR, MMM$80K
    Filing ↗
  • FARRAGUT PARTNERS LLPGILEAD SCIENCES INC. · 2026 Q3 · MMM, HCR$80K
    Filing ↗
  • MILLER STRATEGIES, LLCGILEAD SCIENCES, INC. · 2026 Q3 · HCR, BUD, MMM$150K
    Filing ↗

Government Contracts

Federal awards to gilead sciences · USAspending
$15KAwarded · 1 contract on record
  • Department of Veterans AffairsLENACAPAVIR (SUNLENCA)$15K
    May 14, 2025 · ↗

U.S. Patents

Recent USPTO applications naming GILEAD SCIENCES, INC.

No USPTO patent applications found for GILEAD SCIENCES, INC..

Annual Financials

From GILD's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$29.44B$28.75B$27.12B$27.28B$27.30B
Operating income$10.02B$1.66B$7.61B$7.33B$9.92B
Net income$8.51B$480.0M$5.67B$4.59B$6.22B
Diluted EPS$6.78$0.38$4.50$3.64$4.93
Operating cash flow$10.02B$10.83B$8.01B$9.07B$11.38B
Cash and equivalentsn/an/an/a$5.41B$5.34B
Total assets$59.02B$58.99B$62.13B$63.17B$67.95B
Shareholders' equity$22.70B$19.33B$22.83B$21.24B$21.07B

As GILEAD SCIENCES, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 2-for-1Stock splitJan 28, 2013
  • 2-for-1Stock splitJun 25, 2007
  • 2-for-1Stock splitSep 7, 2004
  • 2-for-1Stock splitMar 8, 2002
  • 2-for-1Stock splitFeb 22, 2001

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsOct 29, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 8.01, 9.01Material agreement · Direct financial obligation · Other eventsMay 20, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteMay 4, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsApr 28, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureFeb 23, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsFeb 10, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeNov 19, 2025
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsOct 30, 2025
    EDGAR ↗

About GILEAD SCIENCES, INC.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersFOSTER CITY, CA
IncorporatedDE
Former namesGILEAD SCIENCES INC